InMed (CSE: IN; OTCQB: IMLFF) Relies on Expertise To Create Value
Read our Medical Marijuana Compound Report for Free Today!
There will be a sudden wave of "Marijuana Millionaires" in 2017 - will you be one?

13x13x1 READ MORE
Emerging Market Report

Dear Seed Investor, 

Great companies are built from the top down.

In the Cannabis Biotech race, expertise is the octane that makes the engine run. 

InMed is one of the few Cannabis companies with Industry expertise.

This expertise has allowed them to make ground breaking discoveries in cannabinoid drug develoment, in the patents for the biosynthesis of cannabinoids, and invaluable experience in being able to scale those discoveries for production and commercialization. 

That means big returns for investors. 

As CEO Eric Adams says:

“InMed is dedicated to developing industry-leading products in diseases with high unmet medical needs.  One key element in drug development is to ensure that we are working with leading scientists in the field who can contribute their in-depth knowledge to help advance our products,”

We've told you a lot about InMed's proprietary biosynthesis and bioinformatics, but that all comes from a leading team of scientists and advisors with a wealth of knowledge. This team ensures the quality of leading edge programs that will contribute to future growth. 

InMed continues to attract the leading minds in the biotech field, as you can see from their management team and recent advisory team announcements. 


InMed has a world class management team in place with years of industry expertise, and recent announcements have expanded their roster of expertise.

CEO Eric Adams
Mr. Adams has 25+ years’ experience in global biopharmaceutical business development, Sales, Marketing, M&A with enGene, QLT, Advanced Tissue Sciences, Abbott Laboratories, Fresenius AG.

His experience and expertise allows him to steer InMed as they grow for the future. 

Click to hear Eric talk about InMed in two separate interviews

Chief Scientific Office, Dr. Sazzad Hossein

Mr. Hossein is a PhD, M.Sc. with 20+ years of academic/industry experience in drug discovery and product development at Xenon Pharmaceuticals, targeting pain, inflammation and cardiovascular diseases; and Canada’s National Research Council. 

His expertise is instrumental in developing the ground breaking Biosynthesis and Bioinformatic program that has InMed ready to change the biotech game. 

Ben Paterson

In September, InMed had a major announcement, adding Ben Paterson to their team as a consultant. 

InMed (CSE: IN; OTCQB: IMLFF) Retains Consultant Ben Paterson for Biosynthesis Development

Mr. Paterson has nearly four decades of experience in developing pharmaceutical manufacturing and purification processes. He was previously a Senior Engineering Advisor with Eli Lilly and Company, where he spent 37 years, including 24 years in their biosynthesis division. His expertise includes first defining processes in the lab, then scaling up to pilot and commercial scale.

InMed today is poised to do what Eli Lilly did in the 1970's, when a discovery in biosynthesis allowed them to grow to a $73 Billion pharmaceutical giant. InMed will do it, by biosynthesizing cannabinoids instead of Insulin.

Knowing that they are on the cusp of a major boom, InMed went out and retained the services of Mr. Paterson, who helped scale Eli Lilly's biosynthesis into the insulin behemoth they are today. 

Dr. Mauro Maccarone

In a recent announcement, InMed announced the addition of Dr. Mauro Maccarone to its Scientific Advisory Board.

InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board

Dr. Mauro Maccarrone is Professor and Chair of Biochemistry and Molecular Biology at Campus Bio-Medico, University of Rome. He also serves as Director of the Laboratory of Lipid Neurochemistry of the European Center for Brain Research-IRCCS Santa Lucia Foundation in Rome.  Prof. Maccarrone served as the President of the International Cannabinoid Research Society and was the recipient of their 2016 Mechoulam Award. He also served as Chair of the 2015 Gordon Research Conference on Cannabinoid Function in the CNS, and is a founding member of the European Cannabinoid Research Alliance.

In addition to having authored over 460 published papers. Dr. Maccarrone serves as referee or on the editorial boards to numerous scientific journals, including Science, Nature Medicine, JAMA, PNAS, Blood, Brain, Journal of Neuroscience, Frontiers in Molecular Neuroscience, Cannabinoids and Cannabinoid Research. He is also Editor of Biochemistry for the Encyclopedia of Life Sciences. 

Biotech companies are only as strong as their innovation and delivery, which is why InMed's expert and experienced management team and advisors gives them a huge advantage. 

This type of expertise shows investors that InMed is poised to continue making advances in the field of cannabinoid biosynthesis, much like their recent announcements: 

Why InMed's (CSE: IN; OTCQB: IMLFF) Ground Breaking Biosynthesis Program Adds Investor Value

High Profits, 

The Seed Investor


Please see full disclaimers on the website applicable to all content provided by TSI, wherever published or re-published:

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 
32x32x1   32x32x2
9375 E Shea Blvd Ste 100
Scottsdale 85260
©2019, All Rights Reserved  |  Unsubscribe   |   View this in Browser

To keep receiving emails from us, please add us to your address book.